← The library
MOTS-c
researchMetabolic/WeightEvidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions
Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.
PurposeMetabolic / Longevity
MechanismMitochondrial-derived peptide involved in metabolic signaling
EffectsMitochondrial-derived peptide involved in metabolic signaling
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published1 sourced
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
Frequency2-3 times per week
Starting5 mg SC 2x per week
EscalationNo titration ladder. Tiers: lower 5 mg 2x/week for 4 weeks; standard 5 mg 3x/week for 4-6 weeks; higher 10 mg 2-3x/week for 6-8 weeks.
Target5-10 mg per injection
Cycle4-8 weeks on, then an equal time off
Backed only by mouse studies. The only human trial found is of CB4211, a different molecule (an analogue); its doses do not transfer to MOTS-c.
Batches on file1
10 mg99.11%
Cautions & interactions
Not FDA-approved; unknown risks
No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.
CV 1 of 5 — Limited direct cardiovascular evidence.